Recent News for IPIX - Innovation Pharmaceuticals Inc.

Date Title
Jul 13 Innovation Pharmaceuticals – Clinical Trial Testing of Brilacidin Against SARS-CoV-2 (COVID-19) Targeted to Commence Q4 2020
Jul 7 In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial
Jun 17 Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line
Jun 11 Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic
May 26 Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line
May 19 Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity
May 5 Inhibitory Effect of Innovation Pharmaceuticals’ Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute
Apr 27 Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4
Apr 20 Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19
Apr 6 Innovation Pharmaceuticals in Discussions to Advance Brilacidin into Human Trials Against COVID-19
Apr 1 Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19
Mar 17 Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions
Mar 12 Innovation Pharmaceuticals Announces Testing Procedures of Brilacidin Against Coronavirus (COVID-19)
Mar 10 U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week
Mar 9 Innovation Pharmaceuticals Brilacidin Received by U.S. Regional Biocontainment Laboratory; Testing Against Coronavirus (COVID-19)
Mar 6 Innovation Pharmaceuticals Signs Second MTA to Explore Brilacidin as Coronavirus COVID-19 Treatment
Mar 5 Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis
Mar 2 Innovation Pharmaceuticals Provides Scientific Rationale and Clinical Development Perspectives for Brilacidin as a Potential Novel Coronavirus COVID-19 Treatment
Feb 27 Innovation Pharmaceuticals to Ship Brilacidin to U.S. Regional Biocontainment Laboratory for Research Against Coronavirus COVID-19
Feb 24 Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for Coronavirus  (COVID-19)
Feb 21 These are the steps needed for a vaccine to be approved
Feb 18 Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment
Jan 29 Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate
Jan 24 Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug
Jan 17 Innovation Pharmaceuticals Announces Dose Escalation

Back to the Main IPIX Page...